Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nightt… Read more
Vanda Pharmaceuticals Inc (VNDA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.090x
Based on the latest financial reports, Vanda Pharmaceuticals Inc (VNDA) has a cash flow conversion efficiency ratio of -0.090x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.42 Million) by net assets ($327.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vanda Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Vanda Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vanda Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vanda Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PT Berkah Beton Sadaya Tbk
OTCQX:BHBSY
|
0.000x |
|
Potbelly Co
NASDAQ:PBPB
|
0.225x |
|
Regenxbio Inc
NASDAQ:RGNX
|
-0.347x |
|
Hwaxin Environmental Co. Ltd. A
SHE:301265
|
N/A |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
0.046x |
|
Hunan Baili Engineering Sci
SHG:603959
|
0.330x |
|
Der International Home Furnishing Co Ltd
SHE:002631
|
-0.007x |
|
Timbercreek Financial Corp
PINK:TBCRF
|
0.005x |
Annual Cash Flow Conversion Efficiency for Vanda Pharmaceuticals Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Vanda Pharmaceuticals Inc from 2004 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $327.19 Million | $-109.44 Million | -0.334x | -1043.24% |
| 2024-12-31 | $538.55 Million | $-15.76 Million | -0.029x | -224.55% |
| 2023-12-31 | $544.91 Million | $12.80 Million | 0.023x | -61.28% |
| 2022-12-31 | $527.20 Million | $31.98 Million | 0.061x | -52.30% |
| 2021-12-31 | $504.93 Million | $64.21 Million | 0.127x | +11.34% |
| 2020-12-31 | $453.27 Million | $51.77 Million | 0.114x | +2.16% |
| 2019-12-31 | $410.94 Million | $45.95 Million | 0.112x | +2.70% |
| 2018-12-31 | $275.42 Million | $29.99 Million | 0.109x | +821.36% |
| 2017-12-31 | $131.39 Million | $-1.98 Million | -0.015x | +75.54% |
| 2016-12-31 | $131.33 Million | $-8.10 Million | -0.062x | -165.93% |
| 2015-12-31 | $133.03 Million | $12.45 Million | 0.094x | +118.45% |
| 2014-12-31 | $160.82 Million | $-81.55 Million | -0.507x | +43.48% |
| 2013-12-31 | $44.12 Million | $-39.59 Million | -0.897x | +80.21% |
| 2012-12-31 | $9.90 Million | $-44.92 Million | -4.535x | -434.31% |
| 2011-12-31 | $33.47 Million | $-28.41 Million | -0.849x | -193.84% |
| 2010-12-31 | $37.73 Million | $-10.90 Million | -0.289x | -103.93% |
| 2009-12-31 | $23.03 Million | $169.34 Million | 7.353x | +836.30% |
| 2008-12-31 | $46.02 Million | $-45.96 Million | -0.999x | -61.91% |
| 2007-12-31 | $83.73 Million | $-51.64 Million | -0.617x | +68.03% |
| 2006-12-31 | $26.76 Million | $-51.62 Million | -1.929x | -233.96% |
| 2005-12-31 | $30.66 Million | $-17.71 Million | -0.578x | -6.91% |
| 2004-12-31 | $15.94 Million | $-8.61 Million | -0.540x | -- |